Conestat alfa

DRUG3 trials

Sponsors

University Hospital, Basel, Switzerland, University of Cincinnati

Conditions

ACE Inhibitor-Induced AngioedemaAcute Kidney InjuryCoronavirus Infections

Phase 2

Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects

CompletedNCT02869347

University Hospital, Basel, SwitzerlandAcute Kidney Injury

Start: 2017-01-31End: 2018-07-31Updated: 2018-08-08

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

TerminatedNCT04414631

University Hospital, Basel, SwitzerlandCoronavirus Infections

Start: 2020-08-06End: 2021-09-15Updated: 2021-11-09

Phase 3

Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema

Not yet recruitingNCT06679426

University of CincinnatiACE Inhibitor-Induced Angioedema

Start: 2024-12-01End: 2025-12-31Target: 24Updated: 2024-11-07

Related Papers

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

Frontiers in Immunology2023-10-275 citations

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).

2021-01-0425 citations

A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury

JACC: Cardiovascular Interventions2020-03-1119 citations